ValiRx Plc (LON:VAL) is to set up a third centre for the dosing trial of lung cancer treatment VAl401 and will seek permission to release mid-trial data.
A second clinic in Tbilisi, Georgia, has just started recruiting patients, but ValiRx now wants to utilise the City’s Research Institute of Clinical Medicine as a third site.
VAL401 is being developed by Valiseek, a joint venture between ValiRx and Tangent Reprofiling Limited.
Suzy Dilly, ValiSeek’s chief executive, said: "The set-up and planning for the addition of a third site is a statement of confidence and evidence that we are all working towards completing recruitment and collecting good quality data within a reasonable timeframe.
“The amendment for preliminary datalock is important as it allow us both to access early data from the trial and to conduct a robust analysis of the early safety, tolerability and pharmacokinetic data, but without compromising the quality of life and survival data that will continue to be gathered".
Using different clinics will provide the optimal team for the company's trial, she added.
The third site will start to dose patients in April with the period to recruit extended to the end of the second quarter.